Broader equity markets saw significant movement in the days leading up to this report's generation date. The Nasdaq 100 added approximately $3.5 trillion in market capitalisation over four consecutive trading sessions through Wednesday, driven by strong corporate earnings and renewed interest in artificial intelligence spending, according to Bloomberg as cited in the pre-US session brief [Brief - 2026-08-05]. Separately, Red Sea escalation and a weak ADP employment reading were noted as factors influencing the European session, contributing to a mixed macro backdrop against which individual equity filings were assessed.
CVS Health Corp reported trailing twelve-month revenue of $415.1 billion as of 30 June 2026, representing year-over-year growth of 7.3% [SEC 10-Q - CVS - 2026-06-30]. Net income on a TTM basis stood at $4.9 billion, with a net margin of 1.18% and an operating margin of 1.997%. Gross margin was recorded at 7.06%. Earnings per share grew 188.75% year-over-year on a TTM basis, while the price-to-earnings ratio stood at 26.15 and market capitalisation was approximately $126.7 billion. The company held $11.3 billion in cash against total debt of $63.5 billion [SEC 10-Q - CVS - 2026-06-30].
This report was triggered by a new SEC filing associated with CVS Health Corp. At the time of generation, no insider transaction data from Form 4 filings or institutional 13F holding changes were included in the provided context. Accordingly, no characterisation of ownership trends or insider activity is made here.
The 10-year US Treasury yield stood at 4.63% and the 2-year yield at 4.20% as of the report date, producing a normal yield curve spread of 43 basis points [FRED DGS10] [FRED DGS2]. This interest rate environment is relevant context for a company carrying $63.5 billion in total debt, as prevailing borrowing costs influence refinancing conditions across the corporate sector.